Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Nasal Polyposis Treatment Market to Reach US$ 6.8 Bn by 2034, Fueled by Rising Demand for Non-invasive Options: Transparency Market Research, Inc.

      This image opens in the lightbox

      News provided by

      Transparency Market Research

      23 Jul, 2024, 09:45 GMT

      Share this article

      Share this article


      Ongoing research and development are leading to advancements in treatment options, including surgical techniques, medications, and biologics.

      WILMINGTON, Del., July 23, 2024 /PRNewswire/ -- The nasal polyposis treatment market was projected to attain US$ 3.5 billion in 2023. It is likely to garner a 6.3% CAGR from 2024 to 2034, and by 2034, the market for nasal polyposis treatment is expected to attain US$ 6.8 billion.

      The emergence of biologic therapies targeting specific inflammatory pathways involved in nasal polyposis presents significant growth opportunities. Advances in personalized medicine approaches, tailoring treatments based on genetic and molecular characteristics, are expected to enhance treatment efficacy.

      Increasing patient preference for non-invasive or minimally invasive treatment options, such as intranasal corticosteroids and nasal sprays, drives market demand. Nasal polyposis often coexists with conditions like asthma and allergic rhinitis. Integrated treatment approaches that address these comorbidities are gaining traction.

      Make Smart Investment decisions with our data! Download a report sample today: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=53529 

      There is a growing emphasis on improving the quality of life for patients with chronic conditions like nasal polyposis, influencing treatment decisions and market dynamics. Adoption of telemedicine and digital health solutions facilitates remote monitoring and management of nasal polyposis, expanding access to care.

      Educational campaigns and initiatives aimed at raising awareness about nasal polyposis symptoms, diagnosis, and treatment options contribute to early intervention and market growth. Growing interest in complementary and alternative medicine (CAM) approaches, such as acupuncture and herbal remedies, provides niche market opportunities.

      Advancements in diagnostic technologies, such as imaging techniques and biomarker identification, enable early and accurate diagnosis, driving treatment initiation. Increasing research into the genetic basis of nasal polyposis and personalized treatment approaches based on genetic profiling offer potential avenues for targeted therapies.

      Key Findings of Market Report

      • Growing influence of patient advocacy groups in raising awareness, driving research funding, and advocating for improved treatment options and access to care.
      • Integration of nasal polyposis treatment within comprehensive healthcare models, including multi-disciplinary care teams and coordinated care pathways, enhances treatment outcomes.
      • Training programs and initiatives aimed at enhancing healthcare providers' knowledge and skills in diagnosing and managing nasal polyposis improve patient outcomes and market growth.
      • Integration of artificial intelligence, machine learning, and digital platforms in disease management and treatment decision-making enhances precision and efficiency.

      Nasal Polyposis Treatment Market Report Scope:

      Report Coverage

      Details 

      Forecast Period  

      2024-2034

      Base Year  

      2020-2022

      Size in 2023

      US$ 3.5 Bn

      Forecast (Value) in 2034

      US$ 6.8 Bn

      Growth Rate (CAGR) 

      6.3 %

      No. of Pages 

      167 Pages 

      Segments covered 

      By Drug Class, By Route of Administration, By Distribution Channel, By Region

      Market Trends for Nasal Polyposis Treatment

      • By drug class, the monoclonal antibodies segment is expected to boost the growth of the nasal polyposis treatment market. Monoclonal antibodies like mepolizumab and omalizumab target specific inflammatory pathways involved in nasal polyposis, offering targeted and effective treatment options.
      • These biologics have a high specificity for their targets, which can potentially lead to better treatment outcomes with reduced side effects compared to conventional therapies. There is a growing demand for biologic therapies due to their efficacy in treating severe cases of nasal polyposis that are refractory to other treatments.
      • On the basis of route of administration, the nasal administration segment is anticipated to augment the market growth. Nasal administration allows direct delivery of medications to the affected nasal mucosa, optimizing therapeutic efficacy while minimizing systemic side effects. Many patients prefer nasal sprays or drops due to their convenience, ease of use, and non-invasiveness compared to oral or parenteral routes.

      Nasal Polyposis Treatment Market: Key Players

      The competitive landscape of the nasal polyposis treatment market is characterized by the presence of several key players and a mix of pharmaceutical companies, biotechnology firms, and healthcare providers.

      The following companies are well known participants in the nasal polyposis treatment market:

      • Abbott Laboratories
      • Sanofi S.A.
      • AstraZeneca
      • Teva Pharmaceutical Industries Ltd.
      • Johnson & Johnson Services Inc.
      • Pfizer Inc.
      • Novartis AG
      • GSK plc
      • Bayer AG
      • Sun Pharmaceutical Industries Ltd.
      • Cipla Ltd.
      • Mylan N.V.
      • Merck KGaA

      Key Developments

      • In 2021, GSK plc announced that Nucala (Mepolizumab) received approval from the United States FDA for the treatment of chronic bilateral nasal polyposis associated with chronic rhinosinusitis.
      • Additionally, GSK's investigational site in Boise, Idaho, is conducting a study to evaluate the effectiveness and safety of Depemokimab (GSK3511294) in patients with chronic rhinosinusitis with nasal polyposis. This study is currently in Phase 3 trials and is expected to be completed by January 2025.

      Access Your Sample Report:
      https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=53529

      Global Market for Nasal Polyposis Treatment: Regional Outlook

      North America

      • Well-developed healthcare infrastructure in North America supports early diagnosis, access to specialized care, and adoption of advanced treatment modalities for nasal polyposis.
      • Increasing healthcare expenditure in the region allows for higher adoption rates of newer and more expensive treatment options, including biologic therapies and advanced medications.

      Asia Pacific

      • Supportive government policies, healthcare reforms, and initiatives aimed at improving public health infrastructure and expanding healthcare coverage contribute to market expansion.
      • Growing investments in medical research and development by both public and private sectors in Asia Pacific foster innovation in nasal polyposis treatment options and therapies.

      Nasal Polyposis Treatment Market Segmentation

      Drug Class

      • Corticosteroids
      • Nasal Corticosteroids
      • Fluticasone
      • Budesonide
      • Mometasone
      • Triamcinolme
      • Others (Beclomethasone, Ciclesonide, etc.)
      • Oral/Injection Corticosteroids
      • Prednisone
      • Combination
      • Monoclonal Antibodies
      • Mepolizumab
      • Omalizumab
      • Antibiotics
      • Antihistamines
      • Others (Aspirin, Anti-Cholinergic Agent, etc.)

      Route of Administration

      • Nasal
      • Oral
      • Parenteral

      Distribution Channel

      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies

      Region

      • North America
      • Latin America
      • Europe
      • Asia Pacific
      • Middle East & Africa

      Buy this Premium Research Report:
      https://www.transparencymarketresearch.com/checkout.php?rep_id=53529&ltype=S 

      More Trending Report by Transparency Market Research:

      • IV Bags Market Predicted to Reach USD 1.5 billion by 2032, Expanding at a CAGR of 5.8%
      • Electronic Health Records Market likely to surpass USD 50 Bn by 2031, expanding at a 5% CAGR
      • Losartan Market is expected to grow at a CAGR of 4.0% from 2024 to 2034 and reach US$ 2.3 Bn by the end of 2034.
      • Levothyroxine Market is expected to grow at a CAGR of 3.3% from 2024 to 2034 and reach US$ 5.4 Bn by the end of 2034.

      About Transparency Market Research 

      Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

      Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. 

      Contact:
      Transparency Market Research Inc.
      CORPORATE HEADQUARTER DOWNTOWN,
      1000 N. West Street,
      Suite 1200, Wilmington, Delaware 19801 USA
      Tel: +1-518-618-1030
      USA – Canada Toll Free: 866-552-3453
      Website: https://www.transparencymarketresearch.com  
      Email: sales@transparencymarketresearch.com
      Follow Us: LinkedIn | Twitter | Blog | YouTube

      Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.